Experimental Pharmaceutical Shipment Quarantine & Incident Report

Clinical Trial Site Number

Clinical Trial Site Name

Trial Site Full Address

Study Protocol Number

Clinical Trial Phase

Study Sponsor Name

CRO/Monitor Contact Email

Investigational Product Batch/Lot Number

Drug Product Name/INN

Dosage Form

Specify other dosage form:

Strength/Concentration

Shipment Tracking/AWB Number

Carrier/Logistics Provider

Shipment Receipt Date & Time

Total Number of Packages in Shipment

Number of Affected Packages

Was a temperature excursion detected during transit or upon receipt?

Provide preliminary description of the excursion event:

Number of Distinct Temperature Excursions Recorded

Detailed Temperature Excursion Log

Temperature Excursion Severity Classification

Select all temperature monitoring devices used in this shipment

Explain why no monitoring devices were present:

Describe device damage or missing device circumstances:

Was the temperature monitoring device calibrated within the last 12 months?

Upload temperature data logger graph/image files (PDF, JPG, PNG)

Detailed Assessment of Potential Impact on Product Quality & Efficacy

I confirm that temperature data has been reviewed by the site pharmacist or qualified designee

Was any packaging damage observed upon receipt?

Immediate description of damage observed:

Select all types of packaging damage or anomalies detected

Describe extent and location of crushing:

Document size and location of tears/punctures:

Describe moisture evidence and affected areas:

Explain tamper-evident seal compromise details:

Document missing seal numbers or identifiers:

Describe labeling discrepancy:

Detail dosage count variance (expected vs. actual):

Describe broken container evidence:

Document contamination observations:

Upload high-resolution photographs of all damaged packaging (multiple angles)

Was the shipment immediately quarantined upon detection of issues?

Explain why immediate quarantine was not possible and document interim measures:

Physical Quarantine Location (room/area identifier)

Quarantine Secured By (name of personnel)

Quarantine Initiated Date & Time

Is the quarantine area temperature-monitored and within specified range?

Document quarantine area temperature conditions and corrective actions:

Chain of Custody Documentation - Personnel Who Handled Shipment from Receipt to Quarantine

Were there any breaks in documented chain of custody?

Describe custody break circumstances and risk assessment:

I confirm that quarantined product is physically segregated and clearly labeled with QUARANTINE - DO NOT USE status

Is immediate replacement of quarantined investigational product required to maintain trial continuity?

Explain urgency and potential impact on patient visits/treatment schedules:

Total Quantity of Replacement Product Required (units)

Estimated Replacement Product Value

Replacement Urgency Level

Requested Dispatch Date for Replacement Product

Preferred Courier/Logistics Provider for Replacement

Special Handling Requirements for Replacement Shipment

Is alternative batch/lot available for immediate dispatch?

Document alternative product sourcing strategy and timeline:

Replacement Product Batch/Lot Number (if identified)

Has the patient/subject been notified of potential treatment delay?

Document patient communication details and consent status:

Cost Center/Account Number for Replacement Shipment

Additional Risk Mitigation Measures for Replacement Shipment

Principal Investigator Full Name

Principal Investigator License/Registration Number

Principal Investigator: Have you reviewed the complete quarantine documentation package?

Principal Investigator Assessment of Impact on Patient Safety & Data Integrity

Principal Investigator Recommended Disposition

Quality Assurance Director Full Name

Quality Assurance Director Certification Number

QA Director: Have you verified that all regulatory requirements have been addressed?

Identify specific regulatory gaps that must be resolved:

QA Director Independent Assessment of GMP/GLP Compliance Status

QA Director Final Disposition Decision

Joint Justification for Final Disposition Decision

Principal Investigator Electronic Signature

Principal Investigator Sign-Off Timestamp

Quality Assurance Director Electronic Signature

Quality Assurance Director Sign-Off Timestamp

Both parties confirm that this decision has been made independently and without conflict of interest

Additional Comments or Escalation Notes